Neutralization of IFN-α with monoclonal antibodies has shown mixed results: sifalimumab improved disease activity and reduced the interferon signature in SLE, whereas rontalizumab did not meet its primary endpoint but suggested efficacy in patients with low pretreatment interferon signatures [383,384,385]. This evidence concerns the gene IFNA1 and systemic lupus erythematosus.